Could NQO1 genotypes impact the results of clinical trials with idebenone?
Clicks: 25
ID: 326683
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
8.1
/100
25 views
22 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #55 of 379 articles by views in Brain research
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 379 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Carelli et al. argue that new insights into how NQO1 influences the response to idebenone warrant reevaluating the results of previous clinical trials, including those in Friedreich ataxia and Duchenne muscular dystrophy, using patient stratification by NQO1 genotype.
| Reference Key |
openalex_W7204442011
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Valério Carelli, Martina Romagnoli, Filippo Fortuna, Claudio Fiorini, Leonardo Caporali, Thomas Klopstock, Chiara La Morgia, Anna Ghelli |
| Journal | Brain research |
| Year | 2026 |
| DOI |
10.1093/brain/awag291
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.